By Karen Roman
Biopharmaceutical company Medera Inc. said the first patient has been dosed in Phase 2 of its MUSIC-HFrEF clinical trial using gene therapy for heart failure with reduced ejection fraction.
The advancement comes after a positive recommendation and shows the treatment’s potential for this form of heart disease, the company stated.
“We are pleased to announce this important milestone for the MUSIC-HFrEF program,” said Ronald Li, Ph.D., Medera’s CEO and co-founder. “The Phase 2 portion will further evaluate SRD-001 and advance our clinical program as we work toward developing next-generation therapeutics for HFrEF patients.”
READ MORE
Final Agenda: 5th Palm Beach CorpGov Forum Nov 5-6 with NYSE and Goldman Sachs
Register for our weekly newsletter HERE
Contact:
Click HERE to follow us on LinkedIn
